In addition, the influence of ERK activity in regulating the CSC phenotype is also reported in gemcitabine-resistant pancreatic cells [58], cisplatin-resistant non-small cell lung cancer cells [59], and docetaxel and carboplatin-resistant ovarian cancer cells [60]. This evidence concerns the gene MAPK1 and non-small cell lung carcinoma.